A Genome-Wide Association Study of Nausea Incidence in Varenicline-Treated Cigarette Smokers.

ABSTRACT:

Introduction

Varenicline is the most efficacious smoking cessation treatment; however, long-term cessation rates tend to be <25%. Nausea, the most common side effect of varenicline, observed in ~28% of individuals treated, peaks early following treatment initiation and reduces cessation success. Genetic variation influences treatment response, however genetic contributors to individual differences in side effects are less understood.

Methods

We conducted a genome-wide association study of nausea incidence at 1 week following the initiation of varenicline treatment (corresponding to the target quit date) in 189 cigarette smokers of European ancestry (NCT01314001). Additive genetic models examining the likelihood of experiencing any versus no nausea controlled for population s

SUBMITTER: Chenoweth MJ 

PROVIDER: S-EPMC8403240 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature